The GluK1 (GluR5) kainate/α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 303-312

  Figueiredo, Taiza H ^a   Qashu, Felicia ^a   Apland, James P ^b   Aroniadou Anderjaska, Vassiliki ^a   Souza, Adriana P ^a   Braga, Maria F M ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 67; SOMAN; TEZAMPANEL;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOLATERAL AMYGDALA; BRAIN DAMAGE; DRUG EFFICACY; EMERGENCY CARE; ENTORHINAL CORTEX; EPILEPTIC STATE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; NEOCORTEX; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; CHEMICAL WARFARE AGENTS; ELECTROENCEPHALOGRAPHY; GAMMA-AMINOBUTYRIC ACID; INTERNEURONS; ISOQUINOLINES; NEURODEGENERATIVE DISEASES; NEURONS; RATS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; SEIZURES; SOMAN; TETRAZOLES;

EID: 78751517808     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.171835     Document Type: Article

References (43)

1. Ali AB, Rossier J, Staiger JF, and Audinat E (2001) Kainate receptors regulate unitary IPSCs elicited in pyramidal cells by fast-spiking interneurons in the neocortex. J Neurosci 21:2992-2999. (Pubitemid 32323480)
2. Apland JP, Aroniadou-Anderjaska V, and Braga MF (2009) Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro. Neuroscience 159:380-389.
3. Apland JP, Figueiredo TH, Qashu F, Aroniadou-Anderjaska V, Souza AP, and Braga MF (2010) Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology. Neurotoxicology 31:485-492.
4. Aroniadou-Anderjaska V, Fritsch B, Qashu F, and Braga MF (2008) Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 78:102-116.
5. Bajgar J (2005) Complex view on poisoning with nerve agents and organophosphates. Acta Medica (Hradec Kralove) 48:3-21.
6. Bettler B, Boulter J, Hermans-Borgmeyer I, O'Shea-Greenfield A, Deneris ES, Moll C, Borgmeyer U, Hollmann M, and Heinemann S (1990) Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron 5:583-595.
7. Bleakman R, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, and Kamboj RK (1996) Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl] decahydroisoquinoline-3 carboxylic-acid. Mol Pharmacol 49:581-585. (Pubitemid 26117641)
8. Braga MF, Aroniadou-Anderjaska V, Li H, and Rogawski MA (2009) Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABA-A receptors on principal neurons. J Pharmacol Exp Ther 330:558-566.
9. Braga MF, Aroniadou-Anderjaska V, Xie J, and Li H (2003) Bidirectional modulation of GABA release by presynaptic glutamate receptor 5 kainate receptors in the basolateral amygdala. J Neurosci 23:442-452. (Pubitemid 36139543)
10. Brown MA and Brix KA (1998) Review of health consequences from high, intermediate, and low-level exposure to organophosphorus nerve agents. J Appl Toxicol 18:393-408.
11. Chen JW, Naylor DE, and Wasterlain CG (2007) Advances in the pathophysiology of status epilepticus. Acta Neurol Scand 115:7-15.
12. Christensen JK, Paternain AV, Selak S, Ahring PK, and Lerma J (2004) A mosaic of functional kainate receptors in hippocampal interneurons. J Neurosci 24:8986-8993.
13. Clarke VR and Collingridge GL (2004) Characterisation of the effects of ATPA, a GLU(K5) kainate receptor agonist, on GABAergic synaptic transmission in the CA1 region of rat hippocampal slices. Neuropharmacology 47:363-372.
14. de Araujo Furtado M, Lumley LA, Robison C, Tong LC, Lichtenstein S, and Yourick DL (2010) Spontaneous recurrent seizures after status epilepticus induced by soman in Sprague-Dawley rats. Epilepsia 51:1503-1510.
15. Gilat E, Kadar T, Levy A, Rabinovitz I, Cohen G, Kapon Y, Sahar R, and Brandeis R (2005) Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats. Toxicol Appl Pharmacol 209:74-85. (Pubitemid 41547219)
16. Gilron I, Max MB, Lee G, Booher SL, Sang CN, Chappell AS, and Dionne RA (2000) Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 68:320-327.
17. Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, and Kapur J (2008) Subunit specific trafficking of GABA(A) receptors during status epilepticus. J Neurosci 28:2527-2538.
18. Gryder DS and Rogawski MA (2003) Selective antagonism of GluR5 kainate receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23:7069-7074.
19. Gundersen HJ, Jensen EB, Kiêu K, and Nielsen J (1999) The efficiency of systematic sampling in stereology-reconsidered. J Microsc 193:199-211.
20. Jane DE, Lodge D, and Collingridge GL (2009) Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 56:90-113.
21. Kaminski RM, Banerjee M, and Rogawski MA (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46:1097-1104.
22. Lallement G, Dorandeu F, Filliat P, Carpentier P, Baille V, and Blanchet G (1998) Medical management of organophosphate-induced seizures. J Physiol Paris 92:369-373.
23. Lallement G, Pernot-Marino I, Baubichon D, Burckhart MF, Carpentier P, and Blanchet G (1994) Modulation of soman-induced neuropathology with an anticonvulsant regimen. NeuroReport 5:2265-2268. (Pubitemid 24374851)
24. Li JM, Zeng YJ, Peng F, Li L, Yang TH, Hong Z, Lei D, Chen Z, and Zhou D (2010) Aberrant glutamate receptor 5 expression in temporal lobe epilepsy lesions. Brain Res 1311:166-174.
25. McDonough JH Jr and Shih TM (1997) Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21:559-579.
26. McDonough JH, McMonagle JD, and Shih TM (2010) Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs. Drug Chem Toxicol 33:279-283.
27. A receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25:7724-7733.
28. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, and Sesma MA (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science 254:1515-1518.
29. Paxinos G and Watson C (2005) The Rat Brain in Stereotaxic Coordinates, 4th Ed, Elsevier, New York.
30. Pereira EF, Aracava Y, Alkondon M, Akkerman M, Merchenthaler I, and Albuquerque EX (2010) Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning. J Mol Neurosci 40:196-203.
31. Pitkänen A, Mathiesen C, Rønn LC, Møller A, and Nissinen J (2007) Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 74:45-54.
32. Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Apland JP, and Braga MF (2010) Diazepam administration after prolonged status epilepticus reduces neurodegeneration in the amygdala but not in the hippocampus during epileptogenesis. Amino Acids 38:189-197.
33. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
34. Rogawski MA, Gryder D, Castaneda D, Yonekawa W, Banks MK, and Lia H (2003) GluR5 kainate receptors, seizures, and the amygdala. Ann NY Acad Sci 985:150-162.
35. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, et al. (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24:596-602.
36. Schmitz C and Hof PR (2000) Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 20:93-114.
37. Shih TM and McDonough JH Jr (1999) Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment. Pharmacol Biochem Behav 64:147-153.
38. Shih TM, Duniho SM, and McDonough JH (2003) Control of nerve agent induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 188:69-80.
39. Smolders I, Bortolotto ZA, Clarke VR, Warre R, Khan GM, O'Neill MJ, Ornstein PL, Bleakman D, Ogden A, Weiss B, et al. (2002) Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 5:796-804.
40. Sunzel M, Paalzow L, Berggren L, and Eriksson I (1988) Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol 25:561-569.
41. Tetz LM, Rezk PE, Ratcliffe RH, Gordon RK, Steele KE, and Nambiar MP (2006) Development of a rat pilocarpine model of seizure/status epilepticus that mimics chemical warfare nerve agent exposure. Toxicol Ind Health 22:255-266.
42. Tomillero A and Moral MA (2008) Gateways to clinical trials. Methods Find Exp Clin Pharmacol 30:643-672.
43. Ullal G, Fahnestock M, and Racine R (2005) Time-dependent effect of kainate-induced seizures on glutamate receptor GluR5, GluR6, and GluR7 mRNA and protein expression in rat hippocampus. Epilepsia 46:616-623. (Pubitemid 40628655)